OP2113, a new drug for chronic hypoxia‐induced pulmonary hypertension treatment in rat
British Journal of Pharmacology · 2023-11 · 180 (21) · 2802-2821
DOI: 10.1111/bph.16174 ↗At a glance
Journal article in British Journal of Pharmacology, published online on 2023-07-25. Written by Lukas Roubenne and 15 co-authors. Institution: Univ. Bordeaux, INSERM, CRCTB, U 1045, F-33000, Bordeaux, France. Major MEDLINE topics: Hypertension, Pulmonary, Heart Failure, Ventricular Dysfunction, Right. Cited 9 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background and Purpose Pulmonary hypertension (PH) is a cardiovascular disease characterised by an increase in pulmonary arterial (PA) resistance leading to right ventricular (RV) failure. Reactive oxygen species (ROS) play a major role in PH. OP2113 is a drug with beneficial effects on cardiac injuries that targets mitochondrial ROS. The aim of the study was to address the in vivo therapeutic effect of OP2113 in PH. Experimental Approach PH was induced by 3 weeks of chronic hypoxia (CH‐PH) in rats treated with OP2113 or its vehicle via subcutaneous osmotic mini‐pumps. Haemodynamic parameters and both PA and heart remodelling were assessed. Reactivity was quantified in PA rings and in RV or left ventricular (LV) cardiomyocytes. Oxidative stress was detected by electron paramagnetic resonance and western blotting. Mitochondrial mass and respiration were measured by western blotting and oxygraphy, respectively. Key Results In CH‐PH rats, OP2113 reduced the mean PA pressure, PA remodelling, PA hyperreactivity in response to 5-HT , the contraction slowdown in RV and LV and increased the mitochondrial mass in RV. Interestingly, OP2113 had no effect on haemodynamic parameters, both PA and RV wall thickness and PA reactivity, in control rats. Whereas oxidative stress was evidenced by an increase in protein carbonylation in CH‐PH, this was not affected by OP2113. Conclusion and Implications Our study provides evidence for a selective protective effect of OP2113 in vivo on alterations in both PA and RV from CH‐PH rats without side effects in control rats.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Univ. Bordeaux, INSERM, CRCTB, U 1045, F-33000, Bordeaux, France.
- OP2 Drugs SAS, Pessac, France.
- Univ. Bordeaux, INSERM, CRCTB, U 1045, IHU Liryc, F-33000, Bordeaux, France.
- CHU de Bordeaux, Service d'Explorations Fonctionnelles Respiratoires, INSERM, U 1045, Bordeaux, France.
Cite
APA
Roubenne, L., Laisné, M., Benoist, D., Campagnac, M., Prunet, B., Pasdois, P., Cardouat, G., Ducret, T., Quignard, J. F., Vacher, P., Baudrimont, I., Marthan, R., Berger, P., Le Grand, B., Freund-Michel, V., & Guibert, C. (2023). OP2113, a new drug for chronic hypoxia‐induced pulmonary hypertension treatment in rat. British Journal of Pharmacology, 180(21), 2802-2821. https://doi.org/10.1111/bph.16174
Vancouver
Roubenne L, Laisné M, Benoist D, Campagnac M, Prunet B, Pasdois P, et al. OP2113, a new drug for chronic hypoxia‐induced pulmonary hypertension treatment in rat. British Journal of Pharmacology. 2023;180(21):2802-2821. doi:10.1111/bph.16174
BibTeX
@article{Roubenne2023,
author = {Roubenne, Lukas and Laisné, Margaux and Benoist, David and Campagnac, Marilyne and Prunet, Bénédicte and Pasdois, Philippe and Cardouat, Guillaume and Ducret, Thomas and Quignard, Jean-François and Vacher, Pierre and Baudrimont, Isabelle and Marthan, Roger and Berger, Patrick and Le Grand, Bruno and Freund-Michel, Véronique and Guibert, Christelle},
title = {OP2113, a new drug for chronic hypoxia‐induced pulmonary hypertension treatment in rat},
journal = {British Journal of Pharmacology},
year = {2023},
volume = {180},
number = {21},
pages = {2802--2821},
doi = {10.1111/bph.16174}
}
EUVIMED